HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

jane departure

This article was originally published in The Rose Sheet

Executive Summary

Sandy Cataldo has resigned as president of jane cosmetics, effective Aug. 2, Estee Lauder division announces. A successor has not yet been named. Cataldo, who took the helm in June 2001, was tasked with improving sales and profits for the struggling mass market teen cosmetics brand. Coinciding with her appointment, Lauder also initiated a $16 mil. restructuring of the business (1"The Rose Sheet" July 2, 2001, p. 4). In her 10 years with Lauder, Cataldo also served as VP-marketing for Clinique USA and Canada and senior VP-marketing for the Estee Lauder brand...

You may also be interested in...



Cataldo joins Bath & Body Works

Sandy Cataldo appointed Bath & Body Works senior VP of emerging markets, Limited Brands announces Aug. 30. Effective immediately, Cataldo will report to Exec VP and General Merchandise Manager Michael Stromberg. Cataldo joins BBW from Estee Lauder, where she most recently worked as president of jane cosmetics. Cataldo, who spent 10 years with Lauder also working for Clinique and Estee Lauder brands, resigned Aug. 2 (1"The Rose Sheet" Aug. 19, 2002, In Brief)...

Lauder's Jane Restructuring Effort Involves $16 Mil. Charge In Q4

Estee Lauder will take a one-time $16 mil. charge in the fiscal fourth quarter (ended June 30) for a restructuring effort aimed at boosting sales and profits for its jane brand of mass market cosmetics, President and CEO Fred Langhammer said during a conference call June 28.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel